News

a.z
Selamoglu, Z. (2025). . , 80(3), 555-568. doi: 10.66224/ARI.2025.80.3.555
Zeliha Selamoglu. "". , 80, 3, 2025, 555-568. doi: 10.66224/ARI.2025.80.3.555
Selamoglu, Z. (2025). '', , 80(3), pp. 555-568. doi: 10.66224/ARI.2025.80.3.555
Selamoglu, Z. . , 2025; 80(3): 555-568. doi: 10.66224/ARI.2025.80.3.555

Archives of Razi Institute
Article 4, Volume 80, Issue 3, January and February 0, Pages 555-568    PDF (576.8 K)
Document Type: مقاله مروری
DOI: 10.66224/ARI.2025.80.3.555
Author
Zeliha Selamoglu*
Nigde University
Supplementary Files
References
  1. Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discovery. 2022;12(1):31-46.
  2. Morris CE, Moury B. Revisiting the concept of host range of plant pathogens. Annual Review of Phytopathology. 2019;57(1):63-90.
  3. Kayser V, Ramzan I. Vaccines and vaccination: history and emerging issues. Human Vaccines & Immunotherapeutics. 2021;17(12):5255-5268.
  4. Kausar S, Said Khan F, Ishaq Mujeeb Ur Rehman M, Akram M, Riaz M, Rasool G, et al. A review: mechanism of action of antiviral drugs. International Journal of Immunopathology and Pharmacology. 2021;35:20587384211002621.
  5. Recht J, Schuenemann VJ, Sánchez-Villagra MR. Host diversity and origin of zoonoses: the ancient and the new. Animals. 2020;10(9):1672.
  6. Chandra S, Wilson JC, Good D, Wei MQ. mRNA vaccines: a new era in vaccine development. Oncology Research. 2024;32(10):1543.
  7. Hou X, Zaks T, Langer R, Dong Y. Lipid nanoparticles for mRNA delivery. Nature Reviews Materials. 2021;6(12):1078-1094.
  8. Omer SB, Yildirim I, Forman HP. Herd immunity and implications for SARS-CoV-2 control. Journal of the American Medical Association. 2020;324(20):2095-2096.
  9. Kaufmann SH, Dorhoi A, Hotchkiss RS, Bartenschlager R. Host-directed therapies for bacterial and viral infections. Nature Reviews Drug Discovery. 2018;17(1):35-56.
  10. Houseini ST, Nemati F, Sattari A, Azadeh M, Bishehkolaei R. Design of crRNA to regulate microRNAs related to metastasis in colorectal cancer using CRISPR-C2c2 (Cas13a) technique. Cell Journal. 2023;25(5):354.
  11. Destoumieux-Garzón D, Mavingui P, Boetsch G, Boissier J, Darriet F, Duboz P, et al. The One Health concept: 10 years old and a long road ahead. Frontiers in Veterinary Science. 2018;5:14.
  12. Boni MF, Lemey P, Jiang X, Lam TT, Perry BW, Castoe TA, et al. Evolutionary origins of the SARS-CoV-2 sarbecovirus lineage responsible for the COVID-19 pandemic. Nature Microbiology. 2020;5(11):1408-1417.
  13. Rodrigue V, Gravagna K, Yao J, Nafade V, Basta NE. Current progress towards prevention of Nipah and Hendra disease in humans: a scoping review of vaccine and monoclonal antibody candidates being evaluated in clinical trials. Tropical Medicine and International Health. 2024;29(5):354-364.
  14. Letko M, Marzi A, Munster V. Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. Nature Microbiology. 2020;5(4):562-569.
  15. Hoffmann M, Kleine-Weber H, Pöhlmann S. A multibasic cleavage site in the spike protein of SARS-CoV-2 is essential for infection of human lung cells. Molecular Cell. 2020;78(4):779-784.
  16. Li JY, Liao CH, Wang Q, Tan YJ, Luo R, Qiu Y, Ge XY. The ORF6, ORF8 and nucleocapsid proteins of SARS-CoV-2 inhibit type I interferon signaling pathway. Virus Research. 2020;286:198074.
  17. Kim D, Lee JY, Yang JS, Kim JW, Kim VN, Chang H. The architecture of SARS-CoV-2 transcriptome. Cell. 2020;181(4):914-921.
  18. Di Giorgio S, Martignano F, Torcia MG, Mattiuz G, Conticello SG. Evidence for host-dependent RNA editing in the transcriptome of SARS-CoV-2. Science Advances. 2020;6(25):eabb5813.
  19. Sun H, Gu R, Tang T, Rai KR, Chen JL. Current perspectives on functional involvement of micropeptides in virus–host interactions. International Journal of Molecular Sciences. 2025;26(8):3651.
  20. Grubaugh ND, Ladner JT, Lemey P, Pybus OG, Rambaut A, Holmes EC, et al. Tracking virus outbreaks in the twenty-first century. Nature Microbiology. 2019;4(1):10-19.
  21. Liu C, Shi Q, Huang X, Koo S, Kong N, Tao W. mRNA-based cancer therapeutics. Nature Reviews Cancer. 2023;23(8):526–543.
  22. Park JW, Lagniton PN, Liu Y, Xu RH. mRNA vaccines for COVID-19: what, why and how. International Journal of Biological Sciences. 2021;17(6):1446.
  23. PREVAC Study Team. Randomized trial of vaccines for Zaire Ebola virus disease. The New England Journal of Medicine. 2022;387(26):2411–2424.
  24. Tukhvatulin AI, Dolzhikova IV, Dzharullaeva AS, Grousova DM, Kovyrshina AV, Zubkova OV, et al. Safety and immunogenicity of rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine against SARS-CoV-2 in healthy adolescents: an open-label, non-randomized, multicenter, phase 1/2, dose-escalation study. Frontiers in Immunology. 2023;14:1228461.
  25. Xiao W, Jiang W, Chen Z, Huang Y, Mao J, Zheng W, Hu Y, Shi J. Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines. Signal Transduction and Targeted Therapy. 2025;10(1):74.
  26. Zhai Y, Han Y, Wang W, Tan W. Advancements in Mpox vaccine development: A comprehensive review of global progress and recent data. Biomedical and Environmental Sciences. 2025;38(2):248–254.
  27. Eastman RT, Roth JS, Brimacombe KR, Simeonov A, Shen M, Patnaik S, et al. Remdesivir: a review of its discovery and development leading to emergency use authorization for treatment of COVID-19. ACS Central Science. 2020;6(5):672–683.
  28. Dunning J, Thwaites RS, Openshaw PJ. Seasonal and pandemic influenza: 100 years of progress, still much to learn. Mucosal Immunology. 2020;13(4):566–573.
  29. Abbott TR, Dhamdhere G, Liu Y, Lin X, Goudy L, Zeng L, et al. Development of CRISPR as an antiviral strategy to combat SARS-CoV-2 and influenza. Cell. 2020;181(4):865–876.
  30. Li Z, Li Z, Cheng X, Wang S, Wang X, Ma S, et al. Intrinsic targeting of host RNA by Cas13 constrains its utility. Nature Biomedical Engineering. 2024;8(2):177–192.
  31. Venu E, Ramya A, Babu PL, Srinivas B, Kumar S, Reddy NK, et al. Exogenous dsRNA-mediated RNAi: mechanisms, applications, delivery methods and challenges in the induction of viral disease resistance in plants. Viruses. 2024;17(1):49.
  32. Wei N, Zheng B, Niu J, Chen T, Ye J, Si Y, Cao S. Rapid detection of genotype II African swine fever virus using CRISPR Cas13a-based lateral flow strip. Viruses. 2022;14(2):179.
  33. Joung J, Ladha A, Saito M, Segel M, Bruneau R, Huang ML, et al. Point-of-care testing for COVID-19 using SHERLOCK diagnostics. medRxiv. 2020. https://doi.org/10.1101/2020.05.04.20091231
  34. Myhrvold C, Freije CA, Gootenberg JS, Abudayyeh OO, Metsky HC, Durbin AF, et al. Field-deployable viral diagnostics using CRISPR-Cas13. Science. 2018;360(6387):444–448.
  35. Broughton JP, Deng X, Yu G, Fasching CL, Servellita V, Singh J, et al. CRISPR–Cas12-based detection of SARS-CoV-2. Nature Biotechnology. 2020;38(7):870–874.
  36. Nzelu CO, Kato H, Peters NC. Loop-mediated isothermal amplification (LAMP): an advanced molecular point-of-care technique for the detection of Leishmania infection. Advances in Medical Imaging, Detection and Diagnosis. 2023:755–781.
  37. Zhang Y, Hunt EA, Tamanaha E, Corrêa IR Jr, Tanner NA. Improved visual detection of DNA amplification using pyridylazophenol metal sensing dyes. Communications Biology. 2022;5(1):999.
  38. Lobato IM, O'Sullivan CK. Recombinase polymerase amplification: basics, applications and recent advances. Trends in Analytical Chemistry. 2018;98:19–35.
  39. Mohanraj J, Durgalakshmi D, Rakkesh RA, Balakumar S, Rajendran S, Karimi-Maleh H. Facile synthesis of paper-based graphene electrodes for point of care devices: a double stranded DNA (dsDNA) biosensor. Journal of Colloid and Interface Science. 2020;566:463–472.
  40. Lino C, Barrias S, Chaves R, Adega F, Martins-Lopes P, Fernandes JR. Biosensors as diagnostic tools in clinical applications. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 2022;1877(3):188726.
  41. Kim J, Campbell AS, de Ávila BE, Wang J. Wearable biosensors for healthcare monitoring. Nature Biotechnology. 2019;37(4):389-406.
  42. Fatima M, An T, Park PG, Hong KJ. Advancements and challenges in addressing zoonotic viral infections with epidemic and pandemic threats. Viruses. 2025;17(3):352.
  43. Mao W, Wang J, Li T, Wu J, Wang J, Wen S, Huang J, Shi Y, Zheng K, Zhai Y, Li X. Hybrid capture-based sequencing enables highly sensitive zoonotic virus detection within the One Health framework. Pathogens. 2025;14(3):264.
  44. Feng Y, Ma J, Sun S, Chi L, Kou Z, Tu C. Epidemiology of animal rabies—China, 2010–2020. China CDC Weekly. 2021;3(39):815.
  45. Qureshi KA, Parvez A, Fahmy NA, Abdel Hady BH, Kumar S, Ganguly A, et al. Brucellosis: epidemiology, pathogenesis, diagnosis and treatment–a comprehensive review. Annals of Medicine. 2023;55(2):2295398.
  46. Erkyihun GA, Alemayehu MB. One Health approach for the control of zoonotic diseases. Zoonoses. 2022;2(1):963.
  47. Kheirallah KA, Al-Mistarehi AH, Alsawalha L, Hijazeen Z, Mahrous H, Sheikali S, et al. Prioritizing zoonotic diseases utilizing the One Health approach: Jordan's experience. One Health. 2021;13:100262.
  48. Ghai RR, Wallace RM, Kile JC, Shoemaker TR, Vieira AR, Negron ME, et al. A generalizable One Health framework for the control of zoonotic diseases. Scientific Reports. 2022;12(1):8588.
  49. McClymont H, Bambrick H, Si X, Vardoulakis S, Hu W. Future perspectives of emerging infectious diseases control: a One Health approach. One Health. 2022;14:100371.
  50. Dadar M, Tiwari R, Sharun K, Dhama K. Importance of brucellosis control programs of livestock on the improvement of One Health. The Veterinary Quarterly. 2021;41(1):137-151.
  51. Shi J, Zeng X, Cui P, Yan C, Chen H. Alarming situation of emerging H5 and H7 avian influenza and effective control strategies. Emerging Microbes & Infections. 2023;12(1):2155072.
  52. Rehman S, Rantam FA, Batool K, Shehzad A, Effendi MH, Witaningrum AM, et al. Emerging threats and vaccination strategies of H9N2 viruses in poultry in Indonesia: a review. F1000Research. 2022;11:548.
  53. Marrana M. Epidemiology of disease through the interactions between humans, domestic animals, and wildlife. In: One Health. Academic Press; 2022:73-111.
  54. Wouters OJ, Shadlen KC, Salcher-Konrad M, Pollard AJ, Larson HJ, Teerawattananon Y, et al. Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment. The Lancet. 2021;397(10278):1023-1034.
  55. Sturgis P, Brunton-Smith I, Jackson J. Trust in science, social consensus and vaccine confidence. Nature Human Behaviour. 2021;5(11):1528-1534.
  56. Rahman M, Adeli M, Schellhorn HE, Jithesh PV, Levy O. Precision vaccinology for infectious diseases. Frontiers in Immunology. 2024;15:1400443.
  57. Ong E, Wong MU, Huffman A, He Y. COVID-19 coronavirus vaccine design using reverse vaccinology and machine learning. Frontiers in Immunology. 2020;11:1581.
  58. Charlton Hume HK, Vidigal J, Carrondo MJ, Middelberg AP, Roldão A, Lua LH. Synthetic biology for bioengineering virus‐like particle vaccines. Biotechnology and Bioengineering. 2019;116(4):919-935.
Statistics
Article View: 677
PDF Download: 952


counter
Journal management system. designed by sinaweb